Please login to the form below

Not currently logged in
Email:
Password:

DMD

This page shows the latest DMD news and features for those working in and with pharma, biotech and healthcare.

Duchenne UK backs Evox dystrophin delivery project

Duchenne UK backs Evox dystrophin delivery project

Oxford University spin-out Evox Therapeutics has won a £656, 000 ($858, 000) grant from a UK medical charity to test its large-molecule delivery technology in Duchenne muscular dystrophy (DMD). ... The funding round will help Evox carry out preclinical

Latest news

  • Entering the era of digital trials Entering the era of digital trials

    A version of the phenomenon affects trials in muscle disorders such as Duchenne muscular dystrophy (DMD). ... One study found kids with DMD walked 11% further if they were offered $50 (£39) to beat their previous distance.

  • Pfizer abandons antibody for Duchenne Pfizer abandons antibody for Duchenne

    Pfizer abandons antibody for Duchenne. Pfizer has halted development of its Duchenne muscular dystrophy (DMD) candidate domagrozumab on disappointing results in a mid-stage efficacy trial. ... Pfizer still has an iron in the DMD fire, in the form of its

  • Mallinckrodt doses first patient in muscular dystrophy trial Mallinckrodt doses first patient in muscular dystrophy trial

    DMD is caused by a lack of functional dystrophin protein, which assists in keeping muscles healthy. ... Mallinckrodt’s step forward comes shortly after another UK biotech, Summit Therapeutics, saw its shares go into freefall in June after its DMD

  • Summit plunges after Duchenne disappointment Summit plunges after Duchenne disappointment

    Shares in UK biotech Summit Therapeutics plunged 80% after its treatment for Duchenne muscular dystrophy (DMD) failed in phase II trials. ... Nevertheless Glyn Edwards warned that cutbacks at the company would now be inevitable after losing its DMD

  • Sarepta soars on positive Duchenne data Sarepta soars on positive Duchenne data

    Some studies have suggested that just 15% dystrophin expression is enough to prevent the contraction-induced muscle injury that characterises DMD. ... around 15% of DMD patients and has to be administered continually to exert its effects.

More from news
Approximately 8 fully matching, plus 31 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2014 Pharma deals during November 2014

    additional $160m more in near-term milestones if drisapersen, the late-stage drug for Duchenne muscular dystrophy (DMD), secures “ early” approval. ... Prosensa has been busy since drisapersen failed a pivotal phase III for DMD (failure to beat a

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Catabasis hires Rick Modi as its chief business officer Catabasis hires Rick Modi as its chief business officer

    We look forward to leveraging his capabilities as we advance our clinical development pipeline, particularly CAT-1004 for Duchenne muscular dystrophy (DMD), and our lipid programmes, CAT-2003 and CAT-2054.”. ... we seek to bring disease-modifying

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • The gene therapy revolution

    for instance to treat haemophilia, rare ophthalmic disorders and for Duchenne muscular dystrophy/DMD), genetic therapies are likely to represent a revolution in medicine over the coming years. ... However, in most areas where genetic treatments are being

More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Cello Health Insight

Cello Health Insight is the global market research arm of Cello Health. With 35 years’ sector experience, we specialise in...

Latest intelligence

OUTiCO win Best in UK Pharmaceutical Outsourcing award
The Corporate LiveWire Healthcare and Life Sciences Awards celebrate global companies and individuals who have excelled over the past 12 months....
artificial-intelligence-in-healthcare.jpg
Artificial Intelligence in Healthcare
Artificial intelligence is already out-diagnosing experts, but would you put a computer in charge of your healthcare? The good, the bad; we take a look....
World Pancreatic Cancer Day 2018: Combating misconceptions in pancreatic cancer
Patients diagnosed with pancreatic cancer face a dismal prognosis, with the disease having the lowest survival rate of all major cancers. In spite of this, pancreatic cancer research is chronically...

Infographics